Home | Welcome to Contract Pharma   
Last Updated Thursday, October 30 2014
Print

Financial Report: Amgen



Published April 23, 2014
Amgen

1Q Revenues: $4.5 billion (+7%)

1Q Earnings: $1.1 billion (-25%)

Comments: Growth in the quarter was driven by newly launched Kyprolis, XGEVA (+25%), Prolia (+38%), and Neulasta sales (+5%). Enbrel sales were down 5% to $924 million and Aranesp sales were down 2% to $177 million, mainly due to lower demand. EPOGEN sales increased 6% to $462 million. Sensipar/Mimpara sales increased 2% to $178 million. Combined sales of Vectibix and Nplate increased 18% to $101 million. R&D expenses were up 17% to $994 million, attributed to the addition of Onyx programs. Earnings were impacted by the end of the ENBREL profit share in 4Q13.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On